The Column Group launches a novel ‘venture-biotech’ model, creating an integrated ecosystem to exclusively fund, discover, and develop single-asset biologic therapies.
The Column Group Raises Over $400 Million For Its New Fund, TCG Labs-Soleil Read More »
The Column Group announced the recruitment of Dr. Dan Nomura to the firm’s renowned group of iPartners. Dr. Nomura is a Professor of Chemical Biology and Molecular Therapeutics in the Department of Chemistry and the Department of Molecular and Cell Biology in the Division of Molecular Therapeutics at the University of California, Berkeley and an
Dr. Dan Nomura joins The Column Group as iPartner Read More »
We are very excited to announce that we have closed the two newest funds of the TCG fund family – The Column Group V (“TCG V”), a $615 million fund focused on early-stage investments, and The Column Group Opportunity III (“TCG Opportunity III”), also $615 million but focused on later stage investments in our companies.
The Column Group Raises $1.23 Billion in Two New Funds Read More »
The Column Group announces the hiring of Dr. Hui Tian. Previously, Dr. Tian was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research. In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer. In a span of 14
Dr. Hui Tian joins The Column Group as Venture Partner Read More »
The Column Group announces the promotion of Dr. Sarah Hymowitz from Venture Partner to Partner. Dr. Hymowitz has been with TCG since 2021.
Dr. Sarah Hymowitz Promoted from Venture Partner to Partner Read More »
The Column Group announces the promotion of Dr. Millie Ray from Principal to Partner. Dr. Ray has been with TCG since 2017.
Dr. Millie Ray Promoted from Principal to Partner Read More »
The Column Group announces the hiring of Mr. Jeff Goater. Previously, Mr. Goater served as Chief Executive Officer of Surface Oncology. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team.
Mr. Jeff Goater joins The Column Group as Venture Partner Read More »
The Column Group announces the hiring of Dr. Sarah Gillmor Hymowitz. Previously, Dr. Hymowitz spent 22 years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the large molecule drug discovery portfolio and mentored project teams on the identification and optimization of more than 35 clinical candidates.
Dr. Sarah Gillmor Hymowitz joins The Column Group as Venture Partner Read More »
Widely considered to be the father of the biotechnology industry, Robert Swanson changed the world when he founded Genentech with Herbert Boyer in 1976. TCG’s new fellowship program pays homage to Robert Swanson’s legacy, empowering the next generation of young visionaries on their quest to better the world through science and medicine. The Column Group
TCG Launches the Swanson Fellowship Program and Dr. Tobias Schmid joins as first Fellow Read More »
TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting innovative new drug discovery company concepts, drawing on their deep scientific expertise, academic and industry networks, and entrepreneurial intuition. The iPartners consist
TCG Announces the Addition of TCG iPartners Read More »
